Skip to main content
  • Saved

made a Post

Neoadjuvant Nivolumab plus Chemotherapy Increased Pathological Complete Response Rate in CheckMate-816 Lung Cancer Trial | AACR | News Releases

Source :

https://www.aacr.org/about-the-aacr/newsroom/news-releases/neoadjuvant-nivolumab-plus-chemotherapy-increased-pathological-complete-response-rate-in-checkmate-816-lung-cancer-trial/

PHILADELPHIA - Adding nivolumab (Opdivo) to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) produced significant improvement of pathological complete response (pCR, primary endpoint) rate to 24 percent, compared with 2.2 percent in the chemotherapy alone arm, with the combination treatment leading to no increase in overall toxicity or delays to surgery, according to data from the phase III trial CheckMate-816, presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.